-+ 0.00%
-+ 0.00%
-+ 0.00%

Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026

Benzinga·10/26/2026 12:49:18
Listen to the news

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.

Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine lines, wrinkles and elasticity after a single dose with the ATR-COSF cosmetic product candidate

Continued improvement seen up to 48 hours

First-in-human study with ATR-COSF initial results anticipated by year end

Further details to be presented in a live presentation at BIO-Europe®